← All trials
NCT05220280
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 6, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Feb 2, 2022
- Last posted
- May 3, 2022
- Enrollment
- 400
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of SherbrookeLead sponsor
- World Health OrganizationCollaborator
- Central Hospital of Kanta-HameCollaborator
- Seinajoki Central HospitalCollaborator
- University of OuluCollaborator
- University of TampereCollaborator
- Kuopio University HospitalCollaborator
- Mikkeli Central HospitalCollaborator
- University of HelsinkiCollaborator
- University of HelsinkiCollaborator
- University of HelsinkiReponsible party - principal investigator
- University of HelsinkiStudy director
- City of HelsinkiCollaborator
- Hyvinkää HospitalCollaborator
- Porvoo HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.